On Mar. 3, 1989, carboplatin (Paraplatin), a drug related to cisplatin, was approved by the U.S. Food and Drug Administration (FDA) for the initial treatment of advanced ovarian carcinoma, used in combination with other chemotherapy agents. Carboplatin is also approved for the palliative treatment of ovarian carcinoma that has recurred after prior chemotherapy, including patients previously treated with cisplatin.

Carboplatin is a type of chemotherapy drug called an alkylating agent. It contains the metal platinum, which binds to and damages the cell’s DNA, preventing it from being repaired or copied. This stops cells from dividing and causes them to die.

Carboplatin is approved to be used alone or with other drugs to treat Ovarian cancer that is advanced. It is used with other chemotherapy as first-line treatment. It is used alone as palliative treatment for disease that has recurred (come back) after earlier chemotherapy.